Avant Technologies INC 8-K filings

Avai Bio, Inc. and Ainnova Tech have mutually agreed to terminate their joint venture and dissolve Ai-Nova Acquisition Corp.

Avant Technologies, Inc. officially changed its name to AVAI BIO, INC. on February 3, 2026, while retaining its AVAI ticker symbol.

Avant Technologies Inc. has formed a 50/50 joint venture, Insulinova Inc., with biotech firm SGAustria Pte. Ltd. to develop diabetes treatments, committing up to $1.5 million in initial capital.

Avant Technologies Inc. has entered a joint venture with SGAustria Pte. Ltd. to form Klothonova Inc., focusing on cell-based treatments for age-related diseases.

Avant Technologies Inc. has filed an application with FINRA to change its corporate name to Ava Bio, Inc. to better reflect its current business.

Avant Technologies terminated its existing Equity Financing Agreement with GHS Investments, LLC, citing misalignment with current business objectives and shareholder interests, and plans to pursue a new agreement with improved terms.

Avant Technologies Inc. and Ainnova Tech Inc. amend their joint venture agreement to include a global license and extend the deadline for satisfying certain conditions, while also considering a potential merger.

Avant Technologies and Ainnova Tech have entered into a joint venture to create Ai-Nova Acquisition Corp, focusing on commercializing AI-driven healthcare technologies for retinal disease detection.

Avant Technologies Inc. has appointed Chris Winter as Chief Operating Officer, effective November 1, 2024, and granted him a significant equity incentive package.

Avant Technologies has terminated its asset purchase agreement with Wired4Health and announced the resignation of its CFO, effective September 9, 2024.

Avant Technologies has entered into an agreement with GHS Investments for up to $20 million in equity financing over the next 24 months.

Avant Technologies has appointed Kenneth L. Waggoner as its new CEO, effective July 10, 2024, and restructured its senior management team.

Avant Technologies has entered a binding letter of intent to acquire up to 50 high-performance supercomputer servers from Flow Wave, LLC for $50 million.

Avant Technologies, Inc. completed the acquisition of technology assets from Wired4Health, Inc. for $2.2 million, paid through a combination of a secured promissory note and preferred stock.

Avant Technologies experiences a significant leadership change with the resignation of its CEO, COO, and VP of Business Development, and the appointment of an Interim CEO, effective April 24, 2024.

Avant Technologies has acquired the assets of Wired4Health for $2.2 million, consisting of a secured promissory note and preferred stock.

Avant Technologies has appointed Angela Harris as its new Chief Operating Officer, effective February 1, 2024, with a compensation package including a base salary, bonus, and equity incentives.

Avant Technologies has appointed Jared Pelski as Vice President of Business Development, with a compensation package including a base salary, bonuses, and equity incentives.